Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) NeoMercazole carbimazole 5mg tablets bottle of 50 (France)
Section 19A approved medicine
(Approval lapsed) NeoMercazole carbimazole 5mg tablets bottle of 50 (France)
Section 19A approval holder
Amdipharm Mercury (Australia) Pty Ltd
Phone
1800 627 680
Approved until
Status
Expired
Medicines in short supply/unavailable
Carbimazole Neo-Mercazole 5mg tablets bottle of 100 - ARTG 194296
Indication(s)
Therapy of hyperthyroidism. Definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. Preparation for thyroidectomy. Before and after radioactive iodine treatment.
Additional information
NeoMercazole carbimazole 5mg tablets bottle of 50 (France) is registered in France and the packaging and product leaflet contains text in the French language. Pharmacists are instructed to direct consumers to disregard the patient leaflet for NeoMercazole carbimazole 5mg tablets bottle of 50 (France) contained within the pack and refer to the Australian Consumer Medicines Information available from: https://www.tga.gov.au .